secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001437749-24-032540
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed to present RewinD-LB Phase 2b data at ILBDC Jan 2025; topline due Dec 2024
--------------------------------------------------------------------------------

- Oral presentation of detailed safety/efficacy results from neflamapimod Phase 2b in DLB at ILBDC on Jan 31, 2025.
- Topline results from RewinD-LB Phase 2b trial expected to be disclosed in December 2024.
- CEO expresses confidence in trial design to detect statistically significant and clinically meaningful difference.
- Baseline patient characteristics from RewinD-LB to be presented at CTAD conference.
- No approved therapies for DLB; neflamapimod aims to address this unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924032540/0001437749-24-032540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924032540/crvo20241030_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-032540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer